Pharmaceutical company Roche: top drugs based on revenue 2022-2023

Roche is one of the top pharmaceutical companies globally. They have a variety of products and medications sold worldwide with oncology being a focus area of the company. In 2023, Roche’s tenth top revenue generating drug was Herceptin (trastuzumab). Herceptin is a drug used in the treatment of some types of breast cancer. The drug generated about 1.6 billion Swiss francs in revenue during 2023, a significant drop compared to the years before.

Roche company overview

Roche is a multinational pharmaceutical company based in Basel, Switzerland. The company has two primary divisions: pharmaceuticals and diagnostics. Roche has experienced exceptional growth in recent years which can be seen in the increasing value of their sales globally. As well as sales, Roche has experienced significant growth in their research and development (R&D) expenditures. Roche has been named a leader in global pharma in several ways but has excelled in producing and selling oncologic pharmaceuticals specifically.

Oncology

Oncology is a branch of medicine that focuses on the diagnosis and treatment of cancer. The number of new cancer drugs under development in the United States is also increasing every year with significant growth recently. Oncology, together with immunology and antidiabetics are the top three therapy areas in the United States based on drug spending.